USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$1.12B
Market Cap
53.84
P/E Ratio
0.32
EPS
$18.15
52 Week High
$3.50
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $68M |
| Total Revenue | $76M |
| Cost Of Revenue | $8.1M |
| Costof Goods And Services Sold | $8.1M |
| Operating Income | -$81M |
| Selling General And Administrative | $35M |
| Research And Development | $122M |
| Operating Expenses | $149M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $11M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8.1M |
| Income Before Tax | -$70M |
| Income Tax Expense | $2.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$73M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$81M |
| Ebitda | -$73M |
| Net Income | -$73M |
| Field | Value (USD) |
|---|---|
| Total Assets | $439M |
| Total Current Assets | $377M |
| Cash And Cash Equivalents At Carrying Value | $224M |
| Cash And Short Term Investments | $224M |
| Inventory | - |
| Current Net Receivables | $173K |
| Total Non Current Assets | $61M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $148M |
| Other Current Assets | $5.1M |
| Other Non Current Assets | - |
| Total Liabilities | $216M |
| Total Current Liabilities | $157M |
| Current Accounts Payable | $17M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.7M |
| Total Non Current Liabilities | $59M |
| Capital Lease Obligations | $43M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $43M |
| Other Current Liabilities | $19M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $223M |
| Treasury Stock | - |
| Retained Earnings | -$439M |
| Common Stock | $6K |
| Common Stock Shares Outstanding | $74M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $68M |
| Total Revenue | $76M |
| Cost Of Revenue | $8.1M |
| Costof Goods And Services Sold | $8.1M |
| Operating Income | -$81M |
| Selling General And Administrative | $35M |
| Research And Development | $122M |
| Operating Expenses | $149M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $11M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8.1M |
| Income Before Tax | -$70M |
| Income Tax Expense | $2.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$73M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$81M |
| Ebitda | -$73M |
| Net Income | -$73M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Monte Rosa Therapeutics, Inc. (GLUE) is a pioneering biopharmaceutical company based in Boston, Massachusetts, focused on developing precision small molecule therapeutics that harness the body's inherent mechanisms for targeted protein degradation. Leveraging its proprietary technology platforms, Monte Rosa aims to address critical unmet medical needs across various therapeutic areas, notably in oncology and autoimmune diseases. With a robust pipeline of innovative drug candidates and a steadfast commitment to scientific excellence, the company is strategically positioned to transform treatment modalities and enhance patient outcomes through its groundbreaking approaches to drug discovery.